CD40 agonism improves anti-tumor T cell priming induced by the combination of radiation therapy plus CTLA4 inhibition and enhances tumor response

Radiation therapy (RT) combined with CTLA4 blockers converts immunosuppressed (cold) mouse triple negative breast cancers (TNBCs) into immune infiltrated (hot) lesions. We have recently shown that targeting the myeloid compartment to improve dendritic cell activation is required for most TNBC-bearin...

Descripción completa

Detalles Bibliográficos
Autores principales: Charpentier, Maud, Formenti, Silvia, Demaria, Sandra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2023
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10506429/
https://www.ncbi.nlm.nih.gov/pubmed/37727740
http://dx.doi.org/10.1080/2162402X.2023.2258011
_version_ 1785107116035407872
author Charpentier, Maud
Formenti, Silvia
Demaria, Sandra
author_facet Charpentier, Maud
Formenti, Silvia
Demaria, Sandra
author_sort Charpentier, Maud
collection PubMed
description Radiation therapy (RT) combined with CTLA4 blockers converts immunosuppressed (cold) mouse triple negative breast cancers (TNBCs) into immune infiltrated (hot) lesions. We have recently shown that targeting the myeloid compartment to improve dendritic cell activation is required for most TNBC-bearing mice to achieve superior therapeutic responses to RT plus CTLA4 inhibitors.
format Online
Article
Text
id pubmed-10506429
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-105064292023-09-19 CD40 agonism improves anti-tumor T cell priming induced by the combination of radiation therapy plus CTLA4 inhibition and enhances tumor response Charpentier, Maud Formenti, Silvia Demaria, Sandra Oncoimmunology Commentary Radiation therapy (RT) combined with CTLA4 blockers converts immunosuppressed (cold) mouse triple negative breast cancers (TNBCs) into immune infiltrated (hot) lesions. We have recently shown that targeting the myeloid compartment to improve dendritic cell activation is required for most TNBC-bearing mice to achieve superior therapeutic responses to RT plus CTLA4 inhibitors. Taylor & Francis 2023-09-15 /pmc/articles/PMC10506429/ /pubmed/37727740 http://dx.doi.org/10.1080/2162402X.2023.2258011 Text en © 2023 The Author(s). Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent.
spellingShingle Commentary
Charpentier, Maud
Formenti, Silvia
Demaria, Sandra
CD40 agonism improves anti-tumor T cell priming induced by the combination of radiation therapy plus CTLA4 inhibition and enhances tumor response
title CD40 agonism improves anti-tumor T cell priming induced by the combination of radiation therapy plus CTLA4 inhibition and enhances tumor response
title_full CD40 agonism improves anti-tumor T cell priming induced by the combination of radiation therapy plus CTLA4 inhibition and enhances tumor response
title_fullStr CD40 agonism improves anti-tumor T cell priming induced by the combination of radiation therapy plus CTLA4 inhibition and enhances tumor response
title_full_unstemmed CD40 agonism improves anti-tumor T cell priming induced by the combination of radiation therapy plus CTLA4 inhibition and enhances tumor response
title_short CD40 agonism improves anti-tumor T cell priming induced by the combination of radiation therapy plus CTLA4 inhibition and enhances tumor response
title_sort cd40 agonism improves anti-tumor t cell priming induced by the combination of radiation therapy plus ctla4 inhibition and enhances tumor response
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10506429/
https://www.ncbi.nlm.nih.gov/pubmed/37727740
http://dx.doi.org/10.1080/2162402X.2023.2258011
work_keys_str_mv AT charpentiermaud cd40agonismimprovesantitumortcellpriminginducedbythecombinationofradiationtherapyplusctla4inhibitionandenhancestumorresponse
AT formentisilvia cd40agonismimprovesantitumortcellpriminginducedbythecombinationofradiationtherapyplusctla4inhibitionandenhancestumorresponse
AT demariasandra cd40agonismimprovesantitumortcellpriminginducedbythecombinationofradiationtherapyplusctla4inhibitionandenhancestumorresponse

Ejemplares similares